News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TYRX Release: Medicare Ruling Concerns Hospital CEOs, but Better Reporting, New Antibiotic Technology Can Lower Cardiac Device Infection Rates


10/11/2012 10:06:16 AM

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--A new Medicare ruling that makes potentially avoidable surgical site infections (SSIs) following cardiac implantable electronic device (CIED) procedures non-reimbursable could have significant financial and quality rating impacts for hospitals, according to a new survey of hospital chief executive officers (CEOs). At the same time, a majority of the CEOs surveyed believed they could influence their electrophysiology/catheterization labs to reduce infection rates, thus managing the risk of higher non-reimbursed costs. Methods cited included leveraging internal reporting to heighten the visibility of CIED SSIs and through the use of antibiotic technologies such as prophylactic antibiotic usage and the AIGISRx® Antimicrobial Envelope, which is specifically designed to help reduce the risk of CIED infections.

Read at BioSpace.com


comments powered by Disqus
TYRX
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES